Skip to content
Company Analysis

Cryo-Cell International, Inc. CCEL

A comprehensive view of key metrics, scores, and financial health for Cryo-Cell International, Inc.

Overview of Cryo-Cell International, Inc.

CCEL ASE
Healthcare Medical Care Facilities Framework: General Corporate Micro Cap
Cryo-Cell International, Inc. (CCEL), is a Micro Cap company, in the Medical Care Facilities industry, last closed at $5.35, about 36.3% undervalued vs fair value, +24.4% 1Y return, ranked 688/1145 in sector.
Metrics Rev Growth -1.3% ROE 15.3% Gross Margin 76.6% Div Yield 9.34%
USD 5.35
2.69%
(Delayed)
• Vol 90d: 98.4%
52-Week Range
Market Cap
$43.10M
Enterprise Value
$50.87M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Fair
Health
Weak
Efficiency
Good
Valuation
Weak
Growth
Fair
Profitability
Fair
Health
Weak
Efficiency
Good
Valuation
Weak
Completeness: 100%
Confidence: 96%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.cryo-cell.com
HQ Oldsmar, FL
Employees 82
Fiscal year Nov 30

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$6
$7
$8
Current: $5.35 +36% vs base

Engine Room Money Flow™

Micro Cap

Corporate Free Cash Flow - Where revenue goes and how value is created

Flow Steps
Revenue
$31.6M
-1.3%%
Gross Profit
$24.2M
0.6%%
Operating Income
$482.4K
-86.1%%
Net Income
-$2.4M
-704.2%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Corporate Free Cash Flow

Quality & Reliability Indicators

Cash Conversion Ratio FY2025
-216.0%

Operating Cash Flow / Net Income

FCF / Net Income - not meaningful while net income is negative (a near-100% ratio here only reflects cash burn tracking accounting losses, not earnings quality)

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$4.8M
90.9% of FCF

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
3
Active Leaks
1/3
Improving
0
High Impact
1
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Cryo-Cell International, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
40
/100
Developing
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.75), suggesting sticky customer base.
  • Cash Generation Consistent Cash generation is consistent (score 0.96), indicating reliable business model.

Key risks

  • ROIC Below WACC or Peers ROIC at 32.1th percentile suggests inefficient capital deployment.
  • Elevated Debt Risk Debt serviceability is weak (score 0.24), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
32
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

vs Industry Peers 92% Coverage
Trade-Off Triangle Visualization A ternary plot showing CCEL's balance between Growth (23.4%), Profitability (49.7%), and Safety (26.9%). Growth 23% Safety 27% Profitability 50%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

24th percentile vs peers
25
Key Signals
Revenue CAGR 3Y 1.3% 43p Rev Growth YoY -1.3% 33p EPS CAGR 3Y -41.4% 10p TSR -45.8% 11p EPS Growth YoY -7.15 4p
Strengths
  • Gross Profit Margin in top 20% of peers (76.6%, 94th percentile)
  • FCF Margin in top 20% of peers (16.6%, 88th percentile)
  • Consistently strong margins across 3 metrics
Risks
  • EPS Growth YoY in bottom 20% of peers (-7.15)

Profitability

52th percentile vs peers
52
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

28th percentile vs peers
28
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Cryo-Cell International, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$7.29
- - -
+36.3% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000